Prakash Investment Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,720 shares of the company's stock, valued at approximately $571,000. Medpace makes up 0.6% of Prakash Investment Advisors LLC's investment portfolio, making the stock its 26th largest holding.
Other large investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Medpace in the fourth quarter worth about $30,000. Stone House Investment Management LLC bought a new position in shares of Medpace during the 3rd quarter worth approximately $33,000. Ashton Thomas Securities LLC purchased a new position in Medpace during the 3rd quarter worth $37,000. Capital Performance Advisors LLP purchased a new position in shares of Medpace in the 3rd quarter valued at approximately $46,000. Finally, True Wealth Design LLC lifted its position in Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company's stock worth $56,000 after acquiring an additional 168 shares during the period. Institutional investors own 77.98% of the company's stock.
Medpace Trading Down 1.2 %
Shares of MEDP stock traded down $4.07 during trading hours on Friday, hitting $340.78. The company's stock had a trading volume of 312,177 shares, compared to its average volume of 302,215. The stock has a market cap of $10.38 billion, a price-to-earnings ratio of 26.98, a P/E/G ratio of 3.81 and a beta of 1.36. The business has a fifty day moving average of $343.13 and a 200-day moving average of $347.20. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $381.44.
Read Our Latest Analysis on MEDP
About Medpace
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Read More
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
